RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
Cap. Flow
-$73.8M
Cap. Flow %
-2.09%
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
1.4 years
Avg Time Held Equity only
1.4 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.4 years

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.1M
3
FOLD icon
Amicus Therapeutics
FOLD
+$40.3M
4
CNC icon
Centene
CNC
+$37.3M
5
STOK icon
Stoke Therapeutics
STOK
+$27.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$82.5M
2
ARRY icon
Array Biopharma Inc
ARRY
+$62.3M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$49.3M
4
PEN icon
Penumbra
PEN
+$47.5M
5
XNCR icon
Xencor
XNCR
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 2.32%
3 Financials 2.17%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CMRX icon
51
DELISTED
Chimerix, Inc.
CMRX
$15.4M 0.44%
3,558,388
+21,670
+0.6% +$66.7K
2016 Q2
12 quarters
HOOK icon
52
DELISTED
HOOKIPA Pharma
HOOK
$12.7M 0.36%
+189,188
New +$20.1M
2019 Q2
0 quarters
PSNL icon
53
Personalis
PSNL
$1.7B
$10.9M 0.31%
+400,000
New +$11.3M
2019 Q2
0 quarters
LOGC
54
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$10.6M 0.3%
814,898
-94,889
-10% -$1.26M
2018 Q4
2 quarters
GBT
55
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.89M 0.28%
188,000
+20,400
+12% +$1.17M
2018 Q4
2 quarters
GTHX icon
56
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.97M 0.25%
+292,734
New +$6.16M
2019 Q2
0 quarters
NVTA
57
DELISTED
Invitae Corporation
NVTA
$8.82M 0.25%
375,375
-998,800
-73% -$21.3M
2015 Q1
17 quarters
BMRN icon
58
CALL
BioMarin Pharmaceuticals
BMRN
$10.7B
$8.56M 0.24%
+100,000
New +$8.55M
2019 Q2
0 quarters
BMRN icon
59
BioMarin Pharmaceuticals
BMRN
$10.7B
$8.32M 0.24%
+97,191
New +$8.31M
2019 Q2
0 quarters
PRNB
60
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$8.1M 0.23%
+244,100
New +$7.62M
2019 Q2
0 quarters
GOSS icon
61
Gossamer Bio
GOSS
$55.3M
$5.51M 0.16%
3,108
-17
-0.5% -$26K
2019 Q1
1 quarter
ONC icon
62
BeOne Medicines Ltd
ONC
$40B
$4.95M 0.14%
39,900
-500
-1% -$63.5K
2018 Q1
5 quarters
AVDR
63
DELISTED
Avedro, Inc Common Stock
AVDR
$4.25M 0.12%
216,200
+91,200
+73% +$1.46M
2019 Q1
1 quarter
FTSV
64
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$2.48M 0.07%
+234,000
New +$3.43M
2019 Q2
0 quarters
OVID icon
65
Ovid Therapeutics
OVID
$424M
$1.36M 0.04%
737,550
– –
2017 Q2
8 quarters
JNCE
66
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.26M 0.04%
254,590
– –
2017 Q1
9 quarters
ELGX
67
DELISTED
Endologix Inc
ELGX
$570K 0.02%
78,755
-1
-0% -$7
2015 Q4
14 quarters
VCEL icon
68
Vericel Corp
VCEL
$2.06B
$316K 0.01%
16,720
– –
2018 Q2
4 quarters
MYOK
69
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$313K 0.01%
6,252
– –
2018 Q2
4 quarters
AMED icon
70
DELISTED
Amedisys
AMED
$282K 0.01%
+2,320
New +$275K
2019 Q2
0 quarters
HZNP
71
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$274K 0.01%
+11,400
New +$289K
2019 Q2
0 quarters
FLXN icon
72
DELISTED
Flexion Therapeutics, Inc.
FLXN
$266K 0.01%
21,630
– –
2018 Q1
5 quarters
ADVM icon
73
DELISTED
Adverum Biotechnologies
ADVM
$264K 0.01%
2,224
– –
2016 Q2
12 quarters
LHCG
74
DELISTED
LHC Group LLC
LHCG
$259K 0.01%
2,166
– –
2018 Q3
3 quarters
NBIX icon
75
Neurocrine Biosciences
NBIX
$13.8B
$231K 0.01%
+2,740
New +$225K
2019 Q2
0 quarters
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2019 Portfolio in Review

As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
  • Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
  • Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
  • Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
  • Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
  • Redmile Group opened 17 new positions and closed 18 in Q2 2019.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.